贝利尤单抗治疗儿童活动性系统性红斑狼疮伴狼疮性肾炎1例  

One case report of active systemic lupus erythematosus in a pediatric patient with lupus nephritis treated by belimumab

作　　者：周仕海 熊亚群 罗平 ZHOU Shi-hai;XIONG Ya-qun;LUO Ping(Department of Pharmacy,Xiangya Hospital,Central South University,Changsha 410008,China;Department of Pharmacy,Guihang Guiyang Hospital,Guiyang 550001,China;Department of Pharmacy,Xiangya Changde Hospital,Changde 415000,China)

机构地区：[1]中南大学湘雅医院药学部,湖南长沙410008 [2]贵航贵阳医院药剂科,贵州贵阳550001 [3]湘雅常德医院药剂科,湖南常德415000

出　　处：《实用药物与临床》2022年第9期818-822,共5页Practical Pharmacy and Clinical Remedies

摘　　要：系统性红斑狼疮(SLE)是一种侵犯全身结缔组织的自身免疫性疾病,可累及多个器官系统,狼疮性肾炎(LN)发生在大约1/3的SLE患者中,是最常见的严重狼疮表现。贝利尤单抗是首个被FDA批准用于SLE治疗的生物制剂,于2020年12月在我国被批准用于儿童SLE,其临床应用经验不足,尤其在儿童SLE伴LN中的应用尚无报道。本文首次报道1例贝利尤单抗治疗SLE伴LN儿童患者的病例,通过对临床表现、用药调整以及疾病转归情况进行总结分析,并结合国内外相关文献,讨论贝利尤单抗在儿童中的疗效、安全性及对贫血的影响,以期为临床合理使用贝利尤单抗提供参考。Systemic lupus erythematosus(SLE)is an autoimmune disease that invades connective tissues throughout the body and can affect multiple organ systems.Lupus nephritis(LN)occurs in approximately one-third of SLE patients and is the most common manifestation of severe lupus.Belimumab is the first biologic agent approved by FDA for the treatment of SLE.It was approved for use in children with SLE in China in December 2020.There is insufficient clinical experience of belimumab,and especially in the treatment of children with SLE and LN,there is no report yet.This article reports for the first time a case of belimumab in the treatment of children with SLE and LN.Through analysis of clinical manifestations,medication adjustments and disease outcomes,and based on extensive literature review,this article discusses the efficacy and safety of belimumab in children,and its effect on anemia,in order to provide a reference for the rational use of belimumab in clinical practice.

关 键 词：贝利尤单抗 儿童 系统性红斑狼疮 狼疮性肾炎 

分 类 号：R725.9[医药卫生—儿科]